Candel Therapeutics, Inc.
NASDAQ:CADL
7.755 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 1.776 | 0 | 0 | 0 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 |
| Cost of Revenue
| 0.249 | 0.251 | 0.312 | 0.306 | 0.295 | 0.287 | 0.276 | 0.258 | 0.238 | 0.215 | 0.178 | 5.265 | 3.292 | 2.753 | 0 | 0 | 1.795 | 1.621 |
| Gross Profit
| -0.249 | -0.251 | 1.464 | -0.306 | -0.295 | -0.287 | -0.245 | -0.227 | -0.207 | -0.184 | -0.147 | -5.234 | -3.261 | -2.722 | 0.031 | 0.031 | -1.764 | -1.59 |
| Gross Profit Ratio
| 0 | 0 | 0.824 | 0 | 0 | 0 | -7.903 | -7.323 | -6.677 | -5.935 | -4.742 | -168.839 | -105.194 | -87.806 | 1 | 1 | -56.903 | -51.29 |
| Reseach & Development Expenses
| 4.73 | 3.851 | 6.946 | 5.845 | 5.934 | 5.469 | 4.972 | 5.376 | 5.022 | 5.417 | 3.854 | 5.265 | 3.292 | 2.753 | 3.534 | 1.813 | 1.795 | 1.621 |
| General & Administrative Expenses
| 3.592 | 3.8 | 3.06 | 3.016 | 3.645 | 4.164 | 3.16 | 3.536 | 3.762 | 3.6 | 3.917 | 2.795 | 2.04 | 1.935 | 2.622 | 0.967 | 0.855 | 0.728 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.592 | 3.8 | 3.06 | 3.016 | 3.645 | 4.164 | 3.16 | 3.536 | 3.762 | 3.6 | 3.917 | 2.795 | 2.04 | 1.935 | 2.622 | 0.967 | 0.855 | 0.728 |
| Other Expenses
| 0 | 0 | 0.012 | 0 | 0 | -0.012 | -0.048 | 5.345 | 4.991 | 5.386 | 15.98 | -8.25 | -12.369 | -0.191 | -4.553 | -0.154 | -0.507 | 0.455 |
| Operating Expenses
| 8.322 | 7.651 | 10.006 | 8.861 | 9.567 | 9.621 | 8.084 | 8.912 | 8.784 | 9.017 | 7.622 | 7.929 | 4.727 | 4.497 | 6.005 | 2.626 | 2.494 | 2.186 |
| Operating Income
| -8.571 | -7.902 | -10.318 | -8.861 | -9.579 | -9.633 | -8.101 | -8.881 | -8.753 | -8.986 | -7.74 | -8.029 | -5.301 | -4.657 | -6.125 | -2.749 | -2.619 | -2.318 |
| Operating Income Ratio
| 0 | 0 | -5.81 | 0 | 0 | 0 | -261.323 | -286.484 | -282.355 | -289.871 | -249.677 | -259 | -171 | -150.226 | -197.581 | -88.677 | -84.484 | -74.774 |
| Total Other Income Expenses Net
| -13.666 | -0.319 | -0.777 | 0.581 | 0.144 | 0.838 | 3.018 | 0.193 | 4.604 | 8.112 | 9.198 | -8.25 | -12.369 | 0.179 | -4.553 | 0.195 | -0.507 | 0.455 |
| Income Before Tax
| -22.237 | -8.221 | -11.095 | -8.435 | -9.614 | -8.795 | -5.083 | -8.688 | -4.149 | -0.874 | 1.596 | -16.162 | -17.08 | -4.478 | -10.478 | -2.554 | -2.876 | -1.772 |
| Income Before Tax Ratio
| 0 | 0 | -6.247 | 0 | 0 | 0 | -163.968 | -280.258 | -133.839 | -28.194 | 51.484 | -521.355 | -550.968 | -144.452 | -338 | -82.387 | -92.774 | -57.161 |
| Income Tax Expense
| 0 | 0.208 | 0.386 | -0.09 | 0.644 | -0.94 | -15.735 | -0.193 | -4.604 | -8.112 | 0.012 | 0.014 | 0.015 | 0.191 | 4.504 | 0.154 | 0.413 | 0.072 |
| Net Income
| -22.237 | -8.221 | -11.095 | -8.435 | -9.614 | -7.855 | 10.652 | -8.495 | 0.455 | 7.238 | 1.596 | -16.162 | -17.08 | -4.478 | -10.478 | -2.554 | -2.876 | -1.772 |
| Net Income Ratio
| 0 | 0 | -6.247 | 0 | 0 | 0 | 343.613 | -274.032 | 14.677 | 233.484 | 51.484 | -521.355 | -550.968 | -144.452 | -338 | -82.387 | -92.774 | -57.161 |
| EPS
| -0.74 | -0.28 | -0.38 | -0.29 | -0.33 | -0.27 | 0.37 | -0.29 | 0.016 | 0.25 | 0.068 | -0.69 | -0.69 | -0.24 | -0.56 | -0.14 | -0.15 | -0.095 |
| EPS Diluted
| -0.74 | -0.28 | -0.38 | -0.29 | -0.33 | -0.27 | 0.37 | -0.29 | 0.016 | 0.25 | 0.068 | -0.69 | -0.69 | -0.24 | -0.56 | -0.14 | -0.15 | -0.095 |
| EBITDA
| -8.322 | -7.651 | -10.006 | -8.861 | -8.878 | -10.115 | -10.797 | -9.045 | -13.535 | -8.821 | -7.413 | -7.877 | -4.689 | -4.44 | -1.415 | -2.55 | -1.948 | -2.123 |
| EBITDA Ratio
| 0 | 0 | -5.634 | 0 | 0 | 0 | -348.29 | -291.774 | -436.613 | -284.548 | -239.129 | -254.097 | -151.258 | -143.226 | -45.645 | -82.258 | -62.839 | -68.484 |